Trial Profile
A phase 2 study to evaluate the efficacy and safety of K-134 for the treatment of intermittent claudication.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2017
Price :
$35
*
At a glance
- Drugs K 134 (Primary)
- Indications Arteriosclerosis obliterans; Embolism and thrombosis; Intermittent claudication; Peripheral arterial disorders
- Focus Therapeutic Use
- Sponsors Kowa Pharmaceutical
- 16 Nov 2011 New trial record